Italy (English)
-
Your selected country is
Italy
- Change country/language
nand
Products
Solutions
Discover & Learn
Resources & Tools
Support
You are now leaving the BD Biosciences website. The site you are about to visit is operated by a third party. The link to this site neither makes nor implies any representation or warranty for any products or services offered on a third-party site and is intended only to enable convenient access to the third-party site and for no other purpose. Do you want to continue?
Old Browser
For the best web browsing experience, please use Chrome, Safari or Firefox, minimum versions 77.0.3865, 12.1.2 and 68, respectively.
Induction DX2
Receptor-Mediated Apoptosis in Human Cells Using anti-Fas/CD95 (Clone DX2)
Materials Required
- A cell line (eg, Jurkat T cells, ATCC TIB 152) or primary cells that can be induced to undergo apoptosis by human Fas mAb.
- Anti-human Fas mAb, Clone DX2 (Cat. No. 555670).
- Recombinant Protein G (SIGMA, Cat. No. P4689). The addition of Protein G to the tissue culture medium can significantly enhance the efficiency of DX2 mAb to induce apoptosis, presumably by cross-linking.
- Tissue culture flasks or tissue culture plates.
- RPMI-1640 medium supplemented with 10% heat- inactivated fetal bovine serum (FBS), 1% L-glutamine and 1% antibiotics (penicillin/streptomycin; 100 U/ml). This supplemented medium is referred to as 'medium' below.
Protocol
- Induction of apoptosis: treat cell suspension (0.5-1 x 10 6 cells/ml) with anti-CD95, clone DX2 (titrate 2-20 µg/ml to determine optimal concentration), and 2 µg/ml Protein G. Negative controls should consist of cells with medium alone (no mAb or Protein G) and cells with medium and Protein G (no mAb).
- Perform a time course to obtain optimum results. An incubation time of 2-16 hr at 37°C is suggested.
- Proceed with assays designed to evaluate induction of apoptosis.
APO-BRDU and APO-DIRECT are trademarks of Phoenix Flow Systems.
23-23971-00
Report a Site Issue
This form is intended to help us improve our website experience. For other support, please visit our Contact Us page.
Successfully submitted.